MedTrace Logo

A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

NCT02662634 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-03-18

No results posted yet for this study

Summary

Feasibility and Safety study of autologous dendritic cell immunotherapy (AGS-003-LNG) in patients with resectable non-small cell lung cancer.

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Interventions

BIOLOGICAL

AGS-003-LNG

autologous dendritic cell immunotherapy

DRUG

Carboplatin

Carboplatin is an anticancer drug ("antineoplastic" or "cytotoxic") chemotherapy drug. Carboplatin is classified as an "alkylating agent."

DRUG

Abraxane

Paclitaxel destroys cancer cells by preventing the normal breakdown of microtubules during cell division.

DRUG

Alimta

By inhibiting the formation of precursor purine and pyrimidine nucleotides, pemetrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cell

DRUG

Cisplatin

Binds to and causes crosslinking of DNA, which ultimately triggers apoptosis

DRUG

Taxol

Mechanism of action involves interference with the normal breakdown of microtubules during cell division.

RADIATION

Radiation Therapy

Causes DNA strand breaks.

Sponsors & Collaborators

  • GU Research Network, LLC

    lead OTHER

Principal Investigators

  • Luke T Nordquist, MD · Cancer Research Network of Nebraska

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2018-03-31
Completion
2018-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02662634 on ClinicalTrials.gov